Ulcerative Colitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult (US)
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs]) that are often effective for those patients with mild to moderate disease. Treatment then progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors (Janssen’s Remicade and AbbVie’s Humira) and a cell adhesion molecule (CAM) inhibitor (Takeda’s Entyvio) are the mainstays of treatment, followed by an IL-12/23 inhibitor (Janssen’s Stelara). However, later-to-market oral targeted therapies, such as Janus-activated kinase (JAK) inhibitors (Pfizer’s Xeljanz / Xeljanz XR and AbbVie’s Rinvoq) and a sphingosine 1-phosphate receptor (S1P-R) modulator (BMS’s Zeposia), are increasing the market competition among later-line targeted therapies. The impending entry of adalimumab biosimilars in the United States will further impact market dynamics.
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult UC patients?
- How have Rinvoq and Zeposia been integrated into the treatment algorithm, and what are their source of business?
- What percentage of adult UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of adult UC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States.
Key companies: AbbVie, Janssen, Pfizer, Takeda, UCB, BMS.
Key drugs: Humira, Remicade, biosimilar infliximab, Entyvio, Stelara, Xeljanz / Xeljanz XR, Simponi, Zeposia, Rinvoq, aminosalicylates, immunosuppressants.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Adult (US)
- Treatment Algorithms CDA Ulcerative Colitis (Adult) US March 2023
Swati Kinger, M.B.A., Healthcare Research & Data Analyst, Immune and Inflammation. Ms. Kinger’s focus is the axial spondyloarthritis market. Previously, she was an associate consultant for a life sciences firm, where she worked on syndicated offerings and ad-hoc requests involving patient journeys, market assessment, and competitive intelligence. She holds a bachelor’s degree in pharmacy from Delhi University and an M.B.A. in pharmacy from the National Institute of Pharmaceutical Education and Research in India.